Product Description
Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. It works to treat GVHD by blocking the signals of the cells that cause GVHD.
Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor,STAT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Incyte
Company Location: WILMINGTON DE 19803
Company CEO: Hervé Hoppenot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 114
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Anemia|Dermatitis, Atopic|Graft vs Host Disease|Hidradenitis Suppurativa|Myelofibrosis|Neurodermatitis|Polycythemia Vera|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Prurigo|Thrombocythemia, Essential|Thrombocytosis|Vitiligo
Phase 2: Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Adenocarcinoma|Anemia, Aplastic|Blast Crisis|Bone Cancer|Bone Marrow Diseases|Bone Marrow Transplantation|Breast Cancer|Breast Diseases|Bronchiolitis Obliterans|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Clear Cell Adenocarcinoma|Colorectal Cancer|Dermatitis|Dermatitis, Seborrheic|Ductal Breast Carcinoma|Ductal Carcinoma|Endometrioid Carcinoma|Eosinophilia|Exanthema|Fallopian Tube Cancer|Hepatitis B, Chronic|Hepatomegaly|Hodgkin Lymphoma|Hypereosinophilic Syndrome|Inflammatory Breast Cancer|Intraductal Noninfiltrating Carcinoma|Juvenile Myelomonocytic Leukemia,|Lichen Planus|Lichen Sclerosus et Atrophicus|Lobular Carcinoma|Lung Cancer|Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic|Lymphohistiocytosis, Hemophagocytic|Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Myelodysplastic Syndrome|Myelodysplastic-Myeloproliferative Diseases|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myeloproliferative Disorders|Ovarian Cancer|Pancreatic Cancer|Peritoneal Cancer|Preleukemia|Prostate Cancer|Serous Cystadenocarcinoma|Stem Cell Transplant
Phase 1: Cachexia|Cytokine Release Syndrome|Healthy Volunteers|Multiple Myeloma|Non-Small-Cell Lung Cancer|Oncology Unspecified|Pancreatic Ductal Carcinoma|Wasting Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AML | P1 |
Recruiting |
Acute Myeloid Leukemia |
2045-03-01 |
23% |
| HEM-iSMART C | P2 |
Not yet recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|Acute Lymphoid Leukemia |
2031-10-01 |
|
| BMT CTN 2203 | P3 |
Recruiting |
Graft vs Host Disease |
2031-01-17 |
66% |
| INCA34176-254 | P2 |
Recruiting |
Graft vs Host Disease |
2030-01-31 |
12% |
| KER050-MF-301 | P2 |
Recruiting |
Myelofibrosis |
2029-06-30 |
|
| KRT-232-115 | P3 |
Recruiting |
Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential |
2029-05-31 |
|
| Pro00113327 | P1 |
Not yet recruiting |
Bronchiolitis Obliterans|Graft vs Host Disease |
2029-01-01 |
23% |
| MCC-23051 | P2 |
Recruiting |
Graft vs Host Disease|Bronchiolitis Obliterans |
2028-12-01 |
12% |
| MITHRIDATE | P3 |
Recruiting |
Polycythemia Vera |
2028-10-31 |
36% |
| XPORT-MF-034 | P3 |
Recruiting |
Myelofibrosis|Anemia |
2028-08-31 |
25% |
| INCA 33989-101 | P1 |
Recruiting |
Myeloproliferative Disorders |
2028-02-29 |
23% |
| NCT06773195 | P2 |
Recruiting |
Myelofibrosis |
2028-01-01 |
50% |
| 2024-515252-20-00 | P2 |
Recruiting |
Myelofibrosis |
2028-01-01 |
|
| NCI-2023-09578 | P2 |
Recruiting |
Lymphohistiocytosis, Hemophagocytic |
2027-11-30 |
12% |
| FRONTJAK-001 | P2 |
Recruiting |
Graft vs Host Disease|Bronchiolitis Obliterans|Stem Cell Transplant |
2027-11-01 |
12% |
| JS110-003-Ib/II | P2 |
Not yet recruiting |
Myelofibrosis |
2027-10-31 |
50% |
| INCB 18424-270 | P2 |
Active, not recruiting |
Lung Cancer|Pancreatic Cancer|Colorectal Cancer|Breast Cancer |
2027-09-30 |
12% |
| RG1124040 | P2 |
Recruiting |
Anemia, Aplastic |
2027-06-01 |
50% |
| MAGIC V | P2 |
Recruiting |
Stem Cell Transplant|Graft vs Host Disease|Bone Marrow Transplantation |
2027-06-01 |
12% |
| INCA34176-254 | P2 |
Recruiting |
Bronchiolitis Obliterans|Graft vs Host Disease |
2027-06-01 |
12% |
| UMCC 2023.109 | P2 |
Recruiting |
Prostate Cancer|Adenocarcinoma |
2027-04-30 |
12% |
| INCB18424-309 | P3 |
Not yet recruiting |
Vitiligo |
2027-04-30 |
25% |
| KPT-IST-391 | P1 |
Recruiting |
Multiple Myeloma |
2027-04-01 |
23% |
| NCI-2024-02814 | P2 |
Not yet recruiting |
Myelofibrosis |
2027-01-01 |
50% |
| CA011-023 | P2 |
Active, not recruiting |
Myelofibrosis |
2026-12-31 |